LEXX has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
LEXX has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
PEG Ratio is defined as the PE Ratio without NRI divided by the growth ratio. The growth rate we use is the 5-Year EBITDA growth rate. As of today, Lexaria Bioscience's PE Ratio without NRI is 0.00. Lexaria Bioscience's 5-Year EBITDA growth rate is 19.10%. Therefore, Lexaria Bioscience's PEG Ratio for today is 0.00.
* The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
The historical rank and industry rank for Lexaria Bioscience's PEG Ratio or its related term are showing as below:
Peter Lynch thinks a company with a P/E ratio equal to its growth rate is fairly valued.
The historical data trend for Lexaria Bioscience's PEG Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lexaria Bioscience Annual Data | |||||||||||||||||||||
Trend | Aug15 | Aug16 | Aug17 | Aug18 | Aug19 | Aug20 | Aug21 | Aug22 | Aug23 | Aug24 | |||||||||||
PEG Ratio | Get a 7-Day Free Trial |
![]() |
![]() |
- | - | - | - | - |
Lexaria Bioscience Quarterly Data | ||||||||||||||||||||
Feb20 | May20 | Aug20 | Nov20 | Feb21 | May21 | Aug21 | Nov21 | Feb22 | May22 | Aug22 | Nov22 | Feb23 | May23 | Aug23 | Nov23 | Feb24 | May24 | Aug24 | Nov24 | |
PEG Ratio | Get a 7-Day Free Trial |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
- | - | - | - | - |
For the Biotechnology subindustry, Lexaria Bioscience's PEG Ratio, along with its competitors' market caps and PEG Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Lexaria Bioscience's PEG Ratio distribution charts can be found below:
* The bar in red indicates where Lexaria Bioscience's PEG Ratio falls into.
PEG Ratio is defined as the PE Ratio without NRI divided by the growth ratio. The ratio we use is the 5-Year EBITDA growth rate.
Lexaria Bioscience's PEG Ratio for today is calculated as
PEG Ratio | = | PE Ratio without NRI | / | 5-Year EBITDA Growth Rate* |
= | / | 19.10 | ||
= | 0.00 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Note: The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
Lexaria Bioscience (NAS:LEXX) PEG Ratio Explanation
To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the P/E ratio divided by the growth ratio. He thinks a company with a P/E ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a P/E of 20, instead of a company growing 10% a year with a P/E of 10.
Thank you for viewing the detailed overview of Lexaria Bioscience's PEG Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
Catherine C. Turkel | director | 19900 MACARTHUR BLVD., SUITE 550, IRVINE CA 92612 |
Vanessa Carle | officer: Secretary | 100 - 740 MCCURDY ROAD, KELOWNA A1 V1X 2P7 |
Gregory Downey | officer: Chief Financial Officer | 100 - 740 MCCURDY ROAD, KELOWNA A1 V1X 2P7 |
Christopher Bunka | director, 10 percent owner, officer: CEO | 1924 BIRKDALE AVE, KELOWNA A1 V1P1R7 |
Reese Albert L Jr | director | |
Brian W. Quigley | director | 100 740 MCCURDY ROAD, KELOWNA A1 23230 |
William Edward Mckechnie | director | 305 MARGARET AVENUE, KITCHENER A6 N2H 6S4 |
Allan Horst Spissinger | officer: CFO | 8131 198A STREET, LANGLEY A1 V2Y 1Y6 |
John Martin Docherty | director, 10 percent owner | 23 MIKELEN DRIVE, PORT PERRY A6 L9L 1V1 |
Baljinder Bhullar | director, officer: CFO | 604 - 700 WEST PENDER, VANCOUVER A1 V6C 1G8 |
Nicholas W Baxter | director | 220 SPRINGFIELD ROAD, ABERDEEN, ABERDEENSHIRE, SCOTLAND X0 AB15 6AU |
Dustin Arthur Elford | director | 888 - 609 WEST HASTINGS STREET, VANCOUVER A1 V6B 4W4 |
Thomas James Ihrke | officer: Sr. VP, Business Development | 38 KRIER LANE, MOUNT PLEASANT SC 29464 |
David Demartini | director, 10 percent owner | 11714 SPRIGGS WAY, HOUSTON TX 77024 |
Leonard Macmillan | director, officer: Vice President - Corp Develop | SUITE 302, 125A - 1030 DENMAN STREET, VANCOUVER A1 V6G 2M6 |
From GuruFocus
By ACCESSWIRE • 02-06-2025
By ACCESSWIRE • 10-08-2024
By ACCESSWIRE • 12-19-2024
By ACCESSWIRE • 10-09-2024
By ACCESSWIRE • 12-09-2024
By ACCESSWIRE • 02-20-2025
By ACCESSWIRE • 02-11-2025
By ACCESSWIRE • 11-25-2024
By ACCESSWIRE • 02-24-2025
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.